Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
Henry
K
K
Melroe
H
H
Huebesch
J
J
Hermundson
J
J
Simpson
J
J
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D004359:Drug Therapy, Combination; D015248:Gemfibrozil / Q000627:therapeutic use*; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000139:chemically induced* / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000009:adverse effects*; D011758:Pyrroles / Q000627:therapeutic use*; D019438:Ritonavir / Q000009:adverse effects; D019258:Saquinavir / Q000009:adverse effects
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D011480:Protease Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D019258:Saquinavir; D019438:Ritonavir; D015248:Gemfibrozil